SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · Real-Time Price · USD
5.66
+0.22 (4.04%)
At close: May 9, 2025, 4:00 PM
5.65
-0.01 (-0.17%)
After-hours: May 9, 2025, 5:58 PM EDT
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States.
Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc.
| Country | United States |
| Founded | 1995 |
| IPO Date | Sep 9, 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Diem Nguyen |
Contact Details
Address: 31 East 62nd Street New York, New York 10065 United States | |
| Phone | 212 672 9100 |
| Website | siga.com |
Stock Details
| Ticker Symbol | SIGA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001010086 |
| CUSIP Number | 826917106 |
| ISIN Number | US8269171067 |
| Employer ID | 13-3864870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Diem Nguyen M.B.A., Ph.D. | Chief Executive Officer and Director |
| Dr. Dennis E. Hruby Ph.D. | Executive Vice President and Chief Scientific Officer |
| Lawrence R. Miller Esq., J.D. | General Counsel and Corporate Secretary |
| Tove C. Bolken | Senior Vice President of Operations and Chief Supply Chain Officer |
| Herb Vloedman | Senior Vice President and Chief Information Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | SCHEDULE 13G/A | Filing |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 8, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 10-K | Annual Report |